| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 365 |
| Cardiovascular Toxicities Associated With Ibrutinib | Journal of the American College of Cardiology | 2019 | 85 |
| P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study | Neuro-Oncology | 2019 | 78 |
| Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response | Gastroenterology | 2019 | 77 |
| Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial | Annals of Oncology | 2019 | 73 |
| Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST | EJNMMI Research | 2019 | 69 |
| Hematologic Complications of Immune Checkpoint Inhibitors | Oncologist | 2019 | 61 |
| Dimethyl fumarate, a two-edged drug: Current status and future directions | Medicinal Research Reviews | 2019 | 53 |
| Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements | Blood | 2019 | 50 |
| Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study | | 2019 | 45 |
| Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) | Digestive and Liver Disease | 2019 | 41 |
| Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study | Journal of Allergy and Clinical Immunology | 2019 | 38 |
| Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib | Clinical Pharmacokinetics | 2019 | 37 |
| Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study | Lung Cancer | 2019 | 34 |
| MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors | Bulletin Du Cancer | 2019 | 34 |
| Healthcare ex Machina: Are conversational agents ready for prime time in oncology? | Clinical and Translational Radiation Oncology | 2019 | 33 |
| A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial | Journal of Medical Internet Research | 2019 | 32 |
| Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations | European Journal of Cancer | 2019 | 25 |
| Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors | Clinical Genitourinary Cancer | 2019 | 22 |
| The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia | Leukemia | 2019 | 22 |
| Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies | Haematologica | 2019 | 21 |
| Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study | Therapeutic Advances in Gastroenterology | 2019 | 20 |
| BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases | British Journal of Surgery | 2019 | 19 |
| Natural history of liver adenomatosis: A long-term observational study | Journal of Hepatology | 2019 | 19 |
| Functional status in a geriatric oncology setting: A review | Journal of Geriatric Oncology | 2019 | 18 |
